What are the indications, dosing regimens, contraindications, and adverse effects of norethindrone?

Norethindrone: Clinical Overview

Indications

Norethindrone is FDA-approved for contraception at 0.35 mg daily as a progestin-only pill (POP), and is also widely used off-label for managing abnormal uterine bleeding, endometriosis, and menstrual suppression 1.

Primary Indication: Contraception

• Approved as continuous oral contraceptive at 0.35 mg daily 1
• Particularly valuable for patients with contraindications to estrogen-containing contraceptives 2

Off-Label Uses (Higher Doses)

• Heavy menstrual bleeding: Norethindrone acetate 2.5-5 mg daily demonstrates pronounced endometrial effects 3
• Endometriosis: Norethindrone acetate 2.5-5 mg daily shows 68.8% patient satisfaction after 5 years of treatment for rectovaginal endometriosis 4
• Acute menstrual bleeding control: Taper regimens achieve 78.9% complete bleeding cessation within 7 days 5

---

Dosing Regimens

Contraception (FDA-Approved)

Take 0.35 mg orally once daily at the same time every day, continuously without interruption between pill packs 1.

• Timing to start: Anytime if reasonably certain patient is not pregnant 2
• Backup contraception needed: If started >5 days after menses began, use barrier methods for 2 days 2
• Critical: Must be taken at the same time daily for maximum effectiveness 1

Menstrual Suppression/Heavy Bleeding (Off-Label)

• Standard dose: Norethindrone acetate 2.5 mg daily, may increase to 5 mg daily 6, 4
• Acute bleeding taper: Higher initial doses tapered over 7-10 days 5
• Important caveat: Patients with obesity or heavy menstrual bleeding are less likely to achieve suppression with 0.35 mg and may require norethindrone acetate at higher doses 6

Endometriosis (Off-Label)

• Norethindrone acetate 2.5-5 mg daily for long-term management 4, 7
• Treatment duration: Can be safely continued for 5 years 4

---

Contraindications

Absolute Contraindications (Based on Estrogen Conversion)

A critical and often overlooked fact: Norethindrone partially converts to ethinylestradiol (EE)—10-20 mg norethindrone corresponds to 20-30 mcg EE 3. This conversion creates estrogen-related contraindications at therapeutic doses:

• Current or history of venous thromboembolism (VTE) - particularly relevant at doses >0.35 mg 3
• Migraine with aura - due to increased stroke risk from estrogen conversion 3
• Active breast cancer - slightly increased risk with long-term use 3
• Current pregnancy (known or suspected)

Relative Contraindications

• High risk for breast cancer (requires clinical consideration) 3
• High risk for thromboembolism at therapeutic doses 3

Important distinction: The 0.35 mg contraceptive dose carries no VTE risk, but therapeutic doses (2.5-5 mg) may be associated with moderately increased risk in a dose-dependent manner 3.

---

Adverse Effects

Common Side Effects

• Irregular bleeding/spotting: Most common reason for discontinuation (54.5% of those who stop) 5
  • More frequent in new OCP users versus switchers 8
  • Typically decreases after cycle 2 8, 9
  • Norethindrone 0.35 mg users experience average 2.6 days intracyclic bleeding per cycle 8

Tolerability Profile

• Contraceptive dose (0.35 mg): Generally well-tolerated, though 48.5% discontinuation rate primarily due to irregular bleeding 5
• Therapeutic doses (norethindrone acetate): 58% tolerate norethindrone acetate well versus 80% for alternative progestins like dienogest 7
• No serious adverse events reported in adolescent populations 5

Estrogen-Related Effects (at Higher Doses)

Due to conversion to ethinylestradiol 3:

• Moderately increased VTE risk (dose-dependent)
• Slightly increased breast cancer risk with long-term use
• Potential stroke risk in women with migraine (theoretical, not studied specifically for norethindrone)

Beneficial Effects

• Positive effects on bone mineral density 3
• Positive or neutral cardiovascular effects at contraceptive doses 3

---

Key Clinical Pitfalls

1. Forgetting the estrogen conversion: At therapeutic doses (≥2.5 mg), norethindrone behaves partially like a combined hormonal contraceptive due to EE conversion. Apply estrogen contraindication screening accordingly 3.

2. Inadequate dosing for menstrual suppression: Younger patients, those with obesity, or heavy menstrual bleeding often fail suppression with 0.35 mg and require norethindrone acetate at higher doses 6.

3. Timing adherence: The 0.35 mg POP requires strict same-time daily dosing for contraceptive efficacy—even small delays reduce effectiveness 1.

4. Premature discontinuation: Counsel patients that irregular bleeding typically improves after the first 2 cycles 8, 9.